Tag: Pfizer

The pharmaceutical giant Pfizer is navigating a challenging start to 2026, caught in a crossfire of financial, regulatory, and competitive ...

Pharmaceutical titan Pfizer finds itself at a pivotal juncture. The era of spectacular pandemic-driven profits is receding, and the company ...

Pfizer shareholders faced a tense weekend as conflicting signals emerged about the pharmaceutical giant's future prospects. While some institutional investors ...

While Pfizer's share price has shown limited movement in recent sessions, significant activity is unfolding behind the scenes. Prominent financial ...

After being largely dismissed by investors due to plummeting COVID-19 revenue and looming patent expirations, pharmaceutical giant Pfizer is suddenly ...

Pfizer is making significant strides in reshaping its post-pandemic trajectory, with recent clinical trial results generating substantial excitement among investors. ...

After an extended period of decline, Pfizer's shares are attracting renewed attention from Wall Street. A powerful combination of regulatory ...

Pharmaceutical titan Pfizer is aggressively reshaping its identity beyond being perceived as a pandemic beneficiary, making a substantial strategic commitment ...

Pfizer's recent $7 billion acquisition of biotechnology firm Metsera has triggered a wave of market skepticism rather than celebration. The ...

In a landmark corporate acquisition, pharmaceutical titan Pfizer has successfully outmaneuvered competitor Novo Nordisk, securing the prized drug developer Metsera ...